{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=50&sponsor=Janssen+Research+%26+Development%2C+LLC",
    "query": {
      "sponsor": "Janssen Research & Development, LLC",
      "page": 50
    },
    "page_size": 10
  },
  "pagination": {
    "page": 50,
    "page_size": 10,
    "total_count": 703,
    "total_pages": 71,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=51&sponsor=Janssen+Research+%26+Development%2C+LLC&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=49&sponsor=Janssen+Research+%26+Development%2C+LLC&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T01:14:46.586Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01640093",
      "title": "A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Abiraterone acetate, 250 mg (uncoated, current commercial tablet)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate, 500 mg (coated, reformulated tablet)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate, 250 mg (coated, reformulated tablet)",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2012-05",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-03-04",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01640093"
    },
    {
      "nct_id": "NCT01369342",
      "title": "A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease",
        "Inflammatory Bowel Disease",
        "IBD",
        "Colitis"
      ],
      "interventions": [
        {
          "name": "Group 1: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Group 2 ustekinumab 130 mg",
          "type": "DRUG"
        },
        {
          "name": "Group 3: ustekinumab approximately 6 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 640,
      "start_date": "2011-07",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-06",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 84,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 81 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01369342"
    },
    {
      "nct_id": "NCT05896761",
      "title": "A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Type 1 (HIV-1)"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Injectable Suspension",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine Injectable Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2021-10-28",
      "completion_date": "2022-08-23",
      "has_results": true,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 10,
      "location_summary": "Bakersfield, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Vero Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05896761"
    },
    {
      "nct_id": "NCT04487080",
      "title": "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Amivantamab",
          "type": "DRUG"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Lazertinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1074,
      "start_date": "2020-09-30",
      "completion_date": "2028-02-16",
      "has_results": true,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 20,
      "location_summary": "Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04487080"
    },
    {
      "nct_id": "NCT02464046",
      "title": "Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "JNJ-42847922",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 28,
      "start_date": "2015-07-27",
      "completion_date": "2015-12-02",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 1,
      "location_summary": "Hollywood, Florida",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02464046"
    },
    {
      "nct_id": "NCT06398457",
      "title": "Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hematologic Malignancy",
        "Bone Marrow Transplant Rejection",
        "Acute Myeloid Leukemia (AML)",
        "Myelodysplastic Syndromes (MDS)",
        "Acute Lymphoblastic Leukemia (ALL), Adult",
        "Multiple Myeloma",
        "Aplastic Anemia",
        "Lymphoma",
        "Non Hodgkin Lymphoma",
        "Hodgkin Lymphoma",
        "Chronic Myeloid Leukemia",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Darzalex Faspro (Daratumumab and hyaluronidase-fihj)",
          "type": "DRUG"
        },
        {
          "name": "JH-DSA Semi-Quant Screen and Response Score",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2024-09-19",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06398457"
    },
    {
      "nct_id": "NCT04898634",
      "title": "A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "JNJ-78278343",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 216,
      "start_date": "2021-07-13",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 3,
      "location_summary": "New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04898634"
    },
    {
      "nct_id": "NCT01134536",
      "title": "Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pain, Postoperative",
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Tapentadol (OS) Oral Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 45,
      "start_date": "2011-10",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-07-14",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Washington D.C., District of Columbia • Meridian, Idaho + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134536"
    },
    {
      "nct_id": "NCT03535558",
      "title": "Fluoroquinolone Associated Disability",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bronchitis",
        "Sinusitis",
        "Urinary Tract Infections"
      ],
      "interventions": [
        {
          "name": "Fluoroquinolone (FQ)",
          "type": "DRUG"
        },
        {
          "name": "Azithromycin (AZ)",
          "type": "DRUG"
        },
        {
          "name": "Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 239306,
      "start_date": "2018-05-17",
      "completion_date": "2018-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-01-29",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03535558"
    },
    {
      "nct_id": "NCT06134804",
      "title": "A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention"
      ],
      "interventions": [
        {
          "name": "ExPEC9V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HD quadrivalent influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 959,
      "start_date": "2023-10-24",
      "completion_date": "2024-07-26",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-11-15T01:14:46.586Z",
      "location_count": 24,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06134804"
    }
  ]
}